Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine
Anna Reznichenko(AstraZeneca (Sweden)), Matthias Kretzler(University of Michigan), Ian Henry(AstraZeneca (Sweden)), Viji Nair(University of Michigan), Laura Barisoni(Duke University), Julie M. Williams(Queen Elizabeth Hospital Birmingham), Carol Moreno Quinn(AstraZeneca (United Kingdom)), Shawn S. Badal(Gilead Sciences (United States)), Timothy Slidel(AstraZeneca (United Kingdom)), Markus Bitzer(Oregon Health & Science University), Mark Tomilo(University of Michigan), Sven Moosmang(Boehringer Ingelheim (Germany)), Damian Fermin(Michigan Medicine), Kevin L. Duffin(Eli Lilly (United States)), Johnna D. Wesley(Novo Nordisk (United States)), Wenjun Ju(Xuzhou Medical College), Ratan V. Bhat(AstraZeneca (Sweden)), Uptal D. Patel(Medical University of Vienna), Jeffrey B. Hodgin(University of Michigan), Anil Karihaloo(Novo Nordisk (United States)), John T. Liles(Gilead Sciences (United States)), Sean Eddy(University of Michigan), Matthew D. Breyer(Johnson & Johnson (United States)), Maria Chiara Magnone(Janssen (Belgium))
Cited by 36
Related Papers
Generation and reproductive phenotypes of mice lacking estrogen receptor β
|Proceedings of the National Academy of Sciences|1998|1.7k
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840